XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.41

+0.1%

9:51 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (12289)	11/21/1999 12:14:00 PM
From: aknahow	of 17367

Thanks, I am disappointed that apparently no one asked for the slides to be faxed to them. Or am I the only klutz that is not set up to receive faxes? The significance of the decline in placebo negative events in the trauma trial seems lost on many posters. This is very important in terms of Neuprex. Certainly not a negative for Neuprex. Also, would have been very difficult for any management to anticipate. Yes with hindsight one can say trial should be run only on subjects that have a negative event already. Not on subjects that may develop problems as a result of loss of blood.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next